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Key Points:  
• Antidepressant medication is frequently listed as causing/exacerbating Orthostatic 
Hypotension (OH). Older adults with Alzheimer Disease (AD) may be particularly 
vulnerable to these effects. 
• Antidepressant medication use was associated with a significantly greater drop in 
blood pressure at 5 minutes in older adults with AD 
• Selective Serotonin Reuptake Inhibitor (SSRI) use in particular may be a risk factor 
for classical OH 
• Screening older antidepressant users, in particular those with AD, may be important 
in terms of medication optimisation and falls prevention 
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Objectives: Antidepressant use is often reported as a risk factor for Orthostatic Hypotension 
(OH), however this relationship has never been explored in those with mild/moderate 
Alzheimer Disease (AD), who may represent a particularly vulnerable cohort 
Methods: We performed a cross-sectional analysis of baseline data from the NILVAD study. 
Participants with mild-moderate AD were recruited from 23 centres in 9 countries. Systolic 
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and Diastolic Blood Pressure (SBP/DBP) was recorded in the seated position and after both 1 
& 5 minutes of standing. OH was defined as a drop of ≥ 20mmHg SBP/≥ 10mmHg DBP. We 
examined the relationship between antidepressant use, orthostatic BP drop and the presence 
of OH, controlling for important covariates.  
Results: Of 509 participants (72.9 ± 8.3 years, 61.9% female), two-fifths (39.1%; 199/509) 
were prescribed a regular antidepressant. Antidepressant use was associated with a 
significantly greater SBP and DBP drop at 5 minutes (β: 1.83, 0.16 – 3.50, p = 0.03 for SBP; 
β: 1.13, 0.02 – 2.25, p<0.05 for DBP). Selective Serotonin Reuptake Inhibitor (SSRI) use was 
associated with a significantly greater likelihood of OH (OR 2.0, 1.1-3.6, p = 0.02). Both 
findings persisted following robust covariate adjustment. 
Conclusions: In older adults with AD, antidepressants were associated with a significantly 
greater SBP/DBP drop at 5 minutes. SSRI use in particular may be a risk factor for OH. This 
emphasises the need to screen older antidepressant users, and particularly those with AD, for 







Whilst antidepressant medication is an efficacious treatment modality in the management of 
depression in later life1, a recent Cochrane review has demonstrated limited efficacy for the 
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use of antidepressant medication for the treatment of depressive symptoms in those 
diagnosed with dementia, who may represent a particularly vulnerable cohort2. In the largest 
trial to date examining the use of both sertraline and mirtazapine for depression in AD, there 
was no significant benefit on depressive symptoms at 13 weeks3. Antidepressant medication 
use in older adults is associated with numerous adverse effects and concerns over safety 
remain4. In fact, the ongoing use of antidepressant medication without appropriate indication 
is included in criteria for inappropriate medication use in older adults5.  
 
A frequently cited potential adverse effect of antidepressant medication use is exacerbation of 
Orthostatic Hypotension (OH)6. OH is independently more common in older people and in 
those with dementia, and is frequently defined by a drop in systolic blood pressure (BP) by 
20 mmHg or greater or a drop in diastolic BP by at least 10 mmHg or greater within 3 
minutes of standing7. As well as producing syncopal symptoms such as dizziness and light-
headedness, OH is a significant risk factor for future falls8. Further, there is evidence that OH 
may act as a risk factor for later cognitive decline and dementia in the first instance9,10.   
 
Whilst the potential risk of antidepressants in causing or exacerbating OH is frequently noted 
in a clinical context, the number of studies actually investigating this relationship remains 
low11. In a study of over 500 participants over a nine year period, both Selective Serotonin 
Reuptake Inhibitors (SSRIs) and Tricyclic Antidepressants (TCAs) were associated with 
orthostatic hypotension12. Further, in a recent study examining the relationship between 
continuous antidepressant users and a matched control cohort, SSRIs, but not other 
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antidepressants were associated with a twofold increased risk of OH11. Finally, on detailed 
analysis of data from the Irish Longitudinal Study on Ageing (TILDA) using beat-to-beat 
blood pressure measurements, antidepressant use was significantly associated with a large-
drop, non-recovery morphology of orthostatic blood pressure behaviour13.  
 
Whilst the few studies in the literature to date examining the link between antidepressants 
and OH have focussed on community-dwelling older adults without dementia, those with a 
diagnosis of dementia may be particularly vulnerable to the adverse orthostatic effects of 
these medications. OH is more common in older adults with dementia14 and those with 
dementia may be particularly vulnerable to the adverse effects of medications15. Further, 
those with dementia have an increased risk of falls16,17. However, the orthostatic effects of 
antidepressants has not been explored in this group, who are frequently prescribed 
antidepressant medication, despite the evidence reporting limited efficacy in this group.  
 
In the current study, we performed a cross-sectional analysis of baseline data from NILVAD, 
a randomised controlled trial of the antihypertensive Nilvadipine in mild-to-moderate 
Alzheimer Disease (AD). We aimed to assess the relationship between antidepressant use and 
blood pressure behaviour at both 1 and 5 minutes post stand in addition to the presence of OH 









Study Setting  
 
The current study is secondary analysis of baseline data from the NILVAD study. NILVAD 
was a randomised clinical trial of the antihypertensive Nilvadipine in mild/moderate AD. It 
was an investigator led study which recruited participants from 23 study sites in 9 Countries 
and received ethical approval from institutional review boards at each country. For details, 
readers are directed to both the main study protocol18 and the main results paper19.  
 
In short, participants were included if they had a diagnosis of Alzheimer Disease as per the 
National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s 
Disease and Related Disorders Association (NINCDS-ADRDA) Criteria. Participants were 
excluded if they exhibited symptoms suggestive of a current depressive episode. Detailed 
inclusion and exclusion criteria have been previously published18. Of relevance to the current 
study, participants using β-blockers, α-blockers and calcium-channel blockers were excluded 
– medications frequently reported to exacerbate orthostatic blood pressure changes and OH11. 
Participants were included if blood pressure measurements were between 100-159 mmHg 
systolic and 65-99 mmHg diastolic. All participants included in the current analysis met all of 
the inclusion criteria for the NILVAD trial (the intention-to-treat population of the trial).  
This article is protected by copyright. All rights reserved.
 
We analysed data from the first two study visits (screening and week 0 visits), prior to 
randomisation to the study drug/placebo in order to evaluate the association between 
antidepressant use, orthostatic blood pressure changes and OH, before any potential 
nilvadipine treatment or trial participation effects may have occurred.  
 
Blood Pressure Measurement & Definition of Orthostatic Hypotension 
 
Participants in the current study had baseline blood pressure assessed at two visits prior to 
randomisation to the study drug (screening visit and at week 0). At both visits, sitting BP was 
measured by trained trial staff using a sphygmomanometer after five minutes in the seated 
position. BP measurement was then repeated after 1 minute and 5 minutes of standing to 
capture orthostatic BP changes.  
 
In order to analyse baseline BP prior to commencement of the trial, we created a systolic BP 
(SBP) and diastolic BP (DBP) variable for each participant consisting of the arithmetic mean 
of both SBP and DBP measurements at screening and week 0 visit. The change in SBP and 
DBP after 1 minute and 5 minutes standing were obtained by subtracting the seated reading 
from the reading after 1 minute/5 minutes of standing to obtain a variable SBP/DBP drop. 
This was calculated for each of the two visits separately. The SBP/DBP drop at both 1 
minute/5 minutes from both visits were then averaged to create a mean drop for both 
This article is protected by copyright. All rights reserved.
SBP/DBP for each participant at 1 and 5 minutes and the mean values used in regression 
analysis (representing the mean drop in SBP/DBP on standing).  
 
In agreement with previous criteria, we defined orthostatic hypotension as a drop in SBP of 
≥ 20 mmHg or a drop in DBP of ≥ 10 mmHg on standing7. This was computed for each visit 
(screening and week 0) separately at both 1 minute (defined as classical OH: cOH) and 5 
minutes (defined as delayed OH: dOH). Participants were considered to have cOH or dOH if 
they met the above criteria for OH on at least one of the two baseline visits.  
 
Antidepressant and Other Medication Use  
 
A comprehensive list of current medication was obtained from participants at baseline. 
Anatomic Therapeutic Classification (ATC) codes were applied to participant medication 
lists in duplicate by two physicians. Antidepressants were coded for by the stem N06 with 
classes coded as follows: N06AA for Tricyclic Antidepressants (TCAs), N06AB for 
Selective-Serotonin Reuptake Inhibitors (SSRIs), N06AX16/N06AX21 for Serotonin-
Noradrenaline Reuptake Inhibitors (SNRI) and the remainder of the N06AX codes as “other 
antidepressants”, including Mirtazepine (N06AX11) and Trazodone (N06AX05).  
 
We created a list of established “culprit” medications which have known influence on 
orthostatic blood pressure changes. Briefly, these included cardiovascular drugs (C02, C03, 
C07, C08, C09), antipsychotic medication (N05A) and other drugs known to exacerbate OH 
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(such as tamsulosin, oxybutynin and tizanidine), in accordance with previous literature6,11. In 
order to account for total medication burden, the total number of prescribed medications was 




Routine demographic information was obtained in a standard fashion at study enrolment (age, 
sex, Body Mass Index (BMI), years of education, years since AD diagnosis). A 
comprehensive medical history was also obtained from participants at baseline. The total 
number of medical comorbidities was calculated per participant to allow us to control for 
total comorbidity in regression models. Further, participants’ medical histories were 
manually screened in duplicate and history of diagnosed depression/anxiety recorded, the 
most common reasons for antidepressant use, in order to allow us control for confounding by 
indication. Dementia severity was assessed using the Clinical Dementia Rating – Sum of 
Boxes (CDR-Sb) and cognitive severity measured using the Alzheimer’s Disease Assessment 




Descriptive statistics were reported as means (± standard deviation) or medians (interquartile 
range) where appropriate. Proportions were expressed as percentages. Univariate statistics 
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employed t-tests and ANOVA (or Kruskall-Wallis H test for non-parametric data) tests. 
Proportions were analysed using the chi-square test.  
 
We used mixed effects linear models in order to assess effect of medication usage on the 
dependent variable, mean drop in systolic or diastolic blood pressure at 1 minute (averaged 
over the two initial visits), with study site as a random effect. In the first instance, 
associations were tested unadjusted (model 1), followed by adjustment for age, sex, BMI, 
baseline seated blood pressure (SBP/DBP as appropriate) and a past medical history of 
depression/anxiety (model 2). In a final model, we incorporated use of other medications with 
potential effects on blood pressure (“culprit” medications as a above) in addition to total 
number of medical comorbidities and total number of medications. In order to analyse the 
effect of antidepressant use on the prevalence of orthostatic hypotension, we performed 
mixed effects logistic regression, again with study site as a random effect. We incorporated 
the same covariates as above in models 1-3.  
 
In the first instance, we tested the association of antidepressant as a binary variable with the 
outcome of interest. Consistent with previous reports showing class-specific effects of 
antidepressant medication on orthostatic BP changes11, we performed analysis for the most 
common three sub-classes: SSRIs, mirtazapine and SNRIs in order to capture any class 
specific effects not seen in the overall analysis. Statistical significance in all instances was 
considered p<0.05.  
 





















Participant Characteristics  
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Overall, 509 participants had baseline assessment completed. In the cohort overall, the mean 
age was 72.9 (±8.3) and the majority of participants were female (61.9%; 315/509). Median 
years since AD diagnosis was 1.1 years (0.5-2.3). Baseline AD severity was 5.3 (±2.8) 
measured using the CDR-Sb. Baseline cognitive impairment measured using the ADAS-Cog 
was 34.5 (±10.6).  
 
Antidepressant Medication Use 
 
Overall, two-fifths (39.1%; 199/509) were prescribed a regular antidepressant medication. A 
small minority were prescribed more than one antidepressant (16/509, 3.1%), with no 
participant prescribed more than one agent from the same class. Prescription of 
antidepressant medication significantly differed by country, with use highest in France 
(62.1% 36/58), Italy (60.0%; 33/55), Greece (43%, 43/100) in comparison to the UK (20%, 
13/65) and the Netherlands (23.1%, 18/78) (χ2 = 47.9, p<0.001).  
 
The most common antidepressant class, prescribed in nearly three-quarters of participants 
was SSRIs (147/199; 73.9%), followed by mirtazapine (N = 24/199; 12.1%), SNRIs (22/199; 
11.1%), Trazadone (16/199; 8.0%) and TCAs (7/199; 3.5%). Within the largest class (SSRIs) 
the most common medications prescribed were escitalopram (N = 49) and citalopram (N = 
45) followed by sertraline (N = 34). Baseline characteristics by antidepressant medication 
prescription, and appropriate univariate statistics are provided in Table 1. 
Antidepressant Use and Orthostatic Blood Pressure Drop  
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Overall there was no significant difference in seated systolic (SBP) or diastolic (DBP) blood 
pressure in those prescribed an antidepressant vs those not prescribed an antidepressant 
[138.0 (± 12.6)/77.1 (± 7.6) mmHg for non-users vs 136.9 (± 11.9)/76.9 (±7.6) mmHg for 
antidepressant users] (t = 1.5, p = 0.1 for SBP, t = 0.3, p = 0.4 for DBP).  
 
Overall, antidepressant use was not associated with a greater drop in SBP or DBP at 1 minute 
under the unadjusted model or either adjusted models. Analysis repeated by antidepressant 
subclass also revealed no significant results and effect estimates are included alongside those 
for antidepressant use in Table 2. On analysing SBP/DBP drop at 5 minutes, there was no 
association between antidepressant use and either drop in SBP or DBP. Under model 2, 
antidepressant use was associated with a greater BP drop at 5 minutes (+1.7 mmHg [0.1 - 
3.4], p = 0.04 greater drop for SBP; +1.13 mmHg [0.1 - 2.2], p = 0.04 for DBP). Finally, 
under model 3, antidepressant use was also associated with a significantly greater BP drop at 
5 minutes (+1.8 mmHg [0.2 - 3.5], p = 0.03 greater drop for SBP; +1.13 mmHg [0.2 - 2.3], p 
= 0.04 for DBP). For results, see Table 3.  
 
Antidepressant Use and Orthostatic Hypotension 
 
Overall, 15.4% (N = 78/509) of study participants met criteria for cOH measured at 1 minute 
at either visit. The prevalence of OH was higher in those prescribed an antidepressant 
(17.6%, 35/164) than those without antidepressant use (13.9%, 43/266). The prevalence of 
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OH was highest in those using SSRIs (20.6%, 28/136) (χ2 = 4.1, p = 0.04) followed by 
mirtazapine (14.3%, 3/21) (χ2 = 0.16, p = 0.69) and SNRIs (10.5%, 2/19) (χ2 = 0.7, p = 0.41).  
 
There was no association between antidepressant use and cOH under an unadjusted model 
(OR 1.3, 0.8 – 2.2, p = 0.3; model 1) or under either model 2 (OR 1.5, 0.9 – 2.7, p = 0.1) or 3 
(OR 1.5, 0.8 – 2.7, p = 0.2). However, on analysis of antidepressant classes, SSRIs, but not 
other antidepressants were significantly associated with the presence of cOH under the 
unadjusted model (OR 1.7, 1.0 – 2.8, p = 0.04; model 1) and under both adjusted models (OR 
2.0, 1.1 – 3.7, p = 0.01 for model 2, OR 2.0, 1.1 – 3.6, p = 0.02 for model 3). See Table 4 
 
Finally, the relationship between antidepressant use and dOH was explored. In the overall 
cohort, 15.2% (77/509) had dOH at either screening/baseline visit. The prevalence of dOH 
was similar in those taking antidepressants (14.6%, N = 26/199) and antidepressant non-users 
(15.5%, N = 48/309) (χ2 = 0.09, p = 0.8). Under model 1 there was no association between 
antidepressant use and dOH (OR 0.9, 0.5 -1.5, p = 0.7). Similarly, no association was seen 
under either adjusted model (OR = 1.5, 0.9 – 2.7, p = 0.9 for model 2; OR 0.9, 0.5 – 1.8, p = 














In the current study, we analysed the relationship between antidepressant use and orthostatic 
BP behaviour over two visits. This is the first study to assess this relationship in those with 
dementia, a group who may be particularly vulnerable to polypharmacy and the adverse 
effects of antidepressant medication. Consistent with previous reports in the literature11,13, we 
demonstrated a significant association between SSRI use and cOH and a significant 
association between antidepressant use and an effect of antidepressant use on delayed BP 
recovery on standing (at 5 minutes).  
 
There was a significant association between antidepressant use and both SBP and DBP at 5 
minutes after standing. These findings support previous reports which demonstrated an 
association between antidepressant use and a large-drop, non-recovery pattern of orthostatic 
BP behaviour in community-dwelling older adults13. Our findings echo this BP behaviour and 
add further insight to the orthostatic effect of ongoing antidepressant use in older adults. It is 
also worthy of note that this drop in BP did not necessarily translate into an increased risk of 
delayed OH in the current analysis. This may be due to the strict cut-off we used for defining 
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orthostatic hypotension in the current analysis. It also may be a result of our 
sphygmomanometer-based oscilometric measurement and not phasic beat-to-beat finometer-
based BP measurement. Nevertheless, our findings demonstrate a significant effect BP drop 
at 5 minutes in antidepressant users.  
 
We also observed a significant association between SSRI use and the prevalence of cOH, 
measured at 1 minute. This finding is consistent those of Briggs et al. who demonstrated an 
SSRI-specific association with cOH in a large community study11. We also observed no 
association between SNRIs, mirtazapine and other antidepressants on orthostatic blood 
pressure behaviour and the prevalence of cOH, however, our study may have been 
underpowered to detect such changes in these subgroups. While statistically non-significant, 
there was a greater overall drop in systolic and diastolic BP at 1 minute post standing, adding 
further evidence to the link between antidepressant use and orthostatic BP behaviour in some 
individuals.  
 
The association between SSRI use and OH is noteworthy and is consistent with previous 
research. SSRIs are frequently viewed as the safest choice of antidepressant class for use in 
older patients, however use has been associated with syncope, fractures and unexplained falls 
20-22. Use of SNRIs on the other hand has not been reported to increase risk of OH, although 
having a low number of participants on these medications in the current study may mean that 
we were underpowered to detect these changes23-24. . All major classes of antidepressants 
have been reported to cause or exacerbate OH, and based on the current study, there is 
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insufficient evidence to conclude that any individual class poses more or less risk than the 
others. Further, an important unanswered question concerns the mechanism by which 
antidepressants may cause OH, which could include effects of psychomotor function and gait 
speed, effects on neurotransmission and vascular tone and also via other effects such as 
hyponatraemia. This is an area where further research is warranted.  
 
The prevalence of antidepressant use in the current study is particularly striking, as is the 
difference between prescribing rates in the different Countries. The reasons for these 
differences are beyond the scope of the current study but may reflect different international 
practice between individual study sites.  
 
Our study has several notable strengths including its international nature (conducted at 23 
sites across 9 countries) in addition to the wealth of information captured on individual 
participants. It also adds a unique perspective in that participants using many medications 
known to exacerbate OH were excluded, as were participants with a history of significant 
cardiovascular disease, enabling us to examine the influence of antidepressants on orthostatic 
BP free from these confounding influences. We also recorded blood pressure across 2 
separate visits and analysed BP behaviour as the mean of readings across these two visits, 
enabling a more accurate picture of overall BP behaviour. Finally, we were able to test this 
association at baseline, before randomisation to the study drug, in order to exclude any 
treatment or trial participation effects.  
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However, our study has several limitations. In the first instance, we recorded blood pressure 
using a manual sphygmomanometer which is reflective of how OH is measured in the 
majority of clinical settings. Continuous phasic beat-to-beat monitoring of blood pressure 
over time using a finometer identifies more rapid changes in BP with each cardiac cycle, 
allowing continuous data of BP behaviour whilst moving from seated to a standing position. 
However, we did analyse BP behaviour over two separate baseline visits in order to enable a 
more accurate estimate of BP prior to randomisation to the study drug. Further our study is 
limited by its cross-sectional nature. Further longitudinal studies in this at risk group are 
warranted. We are also limited by several confounding factors such as polypharmacy, frailty 
and comorbidity in this group, however, we attempted to control for this confounding in the 
current analysis. We controlled for total medication burden, culprit medication use and total 
number of medical comorbidities, attempting to capture the contribution of these important 
confounders.    
 
In conclusion, we performed the first analysis of the association between antidepressant use 
and OH in those with mild-to-moderate AD. We demonstrated a significant association 
between antidepressant use and orthostatic blood pressure drop at 5 minutes post-stand in 
addition to a significant association between SSRI use and classical orthostatic hypotension. 
Our results have important implications for optimal prescribing to treat depression in people 
with dementia, living with dementia, and that consideration in choosing the most appropriate 
antidepressant therapy should include factoring in concurrent symptoms of recurrent falls, 
syncope, and orthostatic hypotension.  
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Tables 
 No Antidepressant 
(N = 310) 
SSRI  
(N = 147) 
Mirtazepine 
(N = 24) 
SNRI  
(N = 22)  
Other Antidepressant 
(N = 23)  
Significance  
Age, Yrs (SD) 73.5 (8.2) 71.5 (8.7) 72.2 (5.2) 72.2 (4.9) 74.4 (8.1) F = 1.55, p = 0.18 
Sex, Female (%) 180 (57.1%) 89 (28.3%) 14 (4.4%)  15 (4.8%) 17 (5.4%) χ2 = 6.61, p = 0.16 
BMI, kg/m2 (SD) 25.0 (4.3) 26.6 (4.4) 24.2 (2.7) 25.7 (3.4) 25.1 (4.3) F = 3.97, p = 0.03* 
Education, Yrs (SD)  16.9 (4.2) 15.8 (4.1) 17.6 (4.1) 15.3 (4.7) 14.4 (3.2) F = 3.67, p<0.001** 
Diagnosis Duration, Yrs (SD)  1.6 (1.7) 1.6 (1.7) 1.5 (1.6) 2.1 (1.8) 2.00 (1.8) F = 0.56, p = 0.69 
Total Medications, Median (IQR) 5 (3-6) 6 (4-7.5) 6 (4-8) 5 (4-8) 6 (5-8) χ2 = 25.37, p <0.001** 
Total Comorbidities, Median (IQR) 3 (2-5) 4 (3-6) 3 (2-5) 4 (3-5) 4 (3-6) χ2 = 16.03, p = 0.003** 
Baseline ADAS-Cog (SD) 33.4 (10.0) 36.2 (11.3) 31.38 (9.7) 39.9 (10.1) 38.4 (12.5) F = 3.92, p = 0.01* 
Baseline CDR-Sb  5.0 (2.7) 5.6 (2.8) 4.8 (2.0) 6.8 (3.1) 6.2 (3.2) F = 2.41, p = 0.05 
 
Table 1. Baseline Demographic and Clinical Characteristics of Participants by Antidepressant Class Use. ANOVA, Kruscal-Wallis tests 
and Chi-square tests were used to compare differences between users of the different subclasses in comparison to those not using any 
antidepressants. * = p<0.05, ** = p <0.001. SSRI: Selective Serotonin Reuptake Inhibitor; SNRI: Selective Serotonin-Noradrenaline Reuptake 
Inhibitor; SD: Standard Deviation; IQR: Interquartile range; BMI: Body Mass Index; ADAS-Cog: Alzheimer Disease Assessment Scale – 
Cognitive Subsection; CDR-Sb: Clinical Dementia Rating – Sum of Boxes 
 




Blood Pressure Drop at 1 Min        
       
Systolic Blood Pressure Model 1 - SBP  Model 2 - SBP  Model 3 - SBP  
 β Coef (95% CI)  P  β Coef (95% CI)  P  β Coef (95% CI)  P  
Antidepressant Use 0.93 (-0.50 – 2.37) 0.20 1.31 (-0.11 – 2.72) 0.07 1.25 (-0.19 – 2.70) 0.09 
SSRI 0.72 (-0.83 – 2.26) 0.37 0.93 (-0.72 – 2.59) 0.27 0.63 (-1.03 – 2.29) 0.46 
Mirtazepine  0.27 (-2.95 – 3.48) 0.87 0.29 (-2.86 – 3.45) 0.86 0.14 (-2.97 – 3.25) 0.93 
SNRI  1.95 (-1.41 – 5.32) 0.26 2.78 (-0.65 – 6.21) 0.11 2.98 (-0.38 – 6.35) 0.08 
Age    -0.00 (-0.09 – 0.08) 0.92 0.02 (-0.07 – 0.11) 0.67 
Gender    -0.09 (-1.45 – 1.28) 0.90 -0.08 (-1.44 – 1.27) 0.91 
BMI    -0.32 (-0.48 - -0.16) 0.01* -0.28 (-0.44 – 0.12) 0.01* 
Baseline BP   0.11 (0.06 – 0.17) 0.01* 0.13 (0.07 – 0.18) 0.01* 
History of Depression/Anxiety   -0.16 (-2.04 – 1.71) 0.86 -0.16 (-2.04 – 1.71) 0.86 
Culprit Medications     2.73 (1.16 – 4.26) 0.01* 
Total Comorbidities      -0.27 (-0.60 – 0.07) 0.12 
Total Medications     0.06 (-0.22 – 0.38) 0.67 
       
Diastolic Blood Pressure Model 1 - DBP  Model 2 - DBP  Model 3 - DBP  
 β Coef (95% CI)  P  β Coef (95% CI)  P  β Coef (95% CI)  P  
Antidepressant Use 0.57 (-0.46 – 1.61) 0.28 1.04 (-0.10 – 2.19) 0.08 1.08 (-0.09 – 2.26) 0.07 
SSRI 0.55 (-0.57 – 1.67) 0.34 1.03 (-0.19 – 2.24) 0.09 1.04 (-0.20 – 2.29) 0.10 
Mirtazepine  -0.79 (-3.11 – 1.53) 0.51 0.48 (-2.82 – 1.87) 0.69 -0.45 (-2.86 – 1.90) 0.71 
SNRI  -0.11 (-2.54 – 2.33) 0.93 0.27 (-2.29 – 2.82) 0.83 0.33 (-2.22 – 2.88) 0.80 
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Age    0.07 (0.00 – 0.13) 0.03* 0.08 (-0.01 – 0.15) 0.02* 
Gender    0.66 (-0.39 – 1.70) 0.22 0.66 (-0.39 – 1.71) 0.22 
BMI    -0.09 (-0.21 – 0.34) 0.16 -0.08 (-0.20 – 0.05) 0.22 
Baseline BP   0.23 (0.16 – 0.30) 0.01* 0.23 (-0.16 – 0.31) 0.01* 
History of Depression/Anxiety   -0.78 (-2.27 – 0.53) 0.224 -0.83 (-2.23 – 0.60) 0.25 
Culprit Medications     -0.30 (-1.44 – 0.86) 0.62 
Total Comorbidities      0.01 (0.25 – 0.25) 0.99 
Total Medications      -0.08 (-0.29 – 0.13) 0.45 
 
Table 2. Mean Drop in Orthostatic Blood Pressure at 1 Minute Blood Pressure and Antidepressant Use. SBP: Systolic Blood Pressure; 
DBP: Diastolic Blood Pressure, BP: Blood Pressure, SSRI: Selective Serotonin Reuptake Inhibitor; SNRI: Serotonin-Noradrenaline Reuptake 















Blood Pressure Drop at 5 Min        
       
Systolic Blood Pressure Model 1 - SBP  Model 2 - SBP  Model 3 - SBP  
 β Coef (95% CI)  P  β Coef (95% CI)  P  β Coef (95% CI)  P  
Antidepressant Use 0.99 (0.48 – 2.46) 0.19 1.73 (0.08 – 3.39) 0.04* 1.83 (0.16 – 3.50) 0.03* 
SSRI 0.62 (-0.97 – 2.21) 0.45 0.93 (-0.72 – 2.59) 0.42 1.40 (-0.40 – 3.16) 0.12 
Mirtazepine  -1.29 (-4.52 – 2.06) 0.45 0.29 (-2.86 – 3.45) 0.89 -1.45 (-4.86 – 1.95) 0.40 
SNRI  2.66 (-0.83 – 6.13) 0.14 2.78 (-0.65 – 6.21) 0.01* 3.75 (-0.11 – 7.40) 0.04 
Age    0.04 (-0.13 – 0.05) 0.42 0.01 (-0.09 – 0.10) 0.96 
Gender    0.01 (-1.63 – 1.42) 0.89 -0.05 (-1.55 – 1.47) 0.96 
BMI    -0.28 (-0.45 - -0.11) 0.01* -0.23 (-0.40 – 0.54) 0.01* 
Baseline BP   0.14 (0.08 – 0.20) 0.01* 0.15 (0.09 – 0.21) 0.01* 
History of Depression/Anxiety   -0.34 (-2.33 – 1.66) 0.74 -0.06 (-2.03 – 1.91) 0.95 
Culprit Medications     1.85 (0.21 – 3.51) 0.03* 
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Total Comorbidities      -0.30 (-0.65 – 0.06) 0.10 
Total Medications     -0.03 (-0.33 – 0.27) 0.86 
       
       
Diastolic Blood Pressure Model 1 - DBP  Model 2 - DBP  Model 3 - DBP  
 β Coef (95% CI)  P  β Coef (95% CI)  P  β Coef (95% CI)  P  
Antidepressant Use 0.75 (-0.24 – 1.73) 0.14 1.13 (0.05 – 2.22) 0.04* 1.13 (0.02 – 2.25) 0.05* 
SSRI 0.57 (-0.49 – 1.63) 0.29 0.99 (-0.15 – 2.15) 0.09 1.04 (-0.20 – 2.29) 0.10 
Mirtazepine  -0.78 (-3.00 – 1.43) 0.49 -0.36 (-2.59 – 1.88) 0.76 -0.45 (-2.86 – 1.90) 0.71 
SNRI  0.72 (-1.59 – 3.02) 0.54 -0.61 (-1.81 – 3.04) 0.62 0.33 (-2.22 – 2.88) 0.80 
Age    0.01 (-0.06 – 0.07) 0.81 0.01 (-0.06 – 0.07) 0.80 
Gender    0.93 (-0.06 – 1.93) 0.07 0.93 (-0.06 – 1.92) 0.07 
BMI    0.03 (-0.08 – 0.15) 0.57 0.04 (-0.08 – 0.15) 0.54 
Baseline BP   0.22 (0.015 – 0.02) 0.01* 0.22 (0.15 – 0.29) 0.01* 
History of Depression/Anxiety   -1.05 (-2.41 – 0.30) 0.13 -1.06 (-2.42 – 0.29) 0.12 
Culprit Medications     -0.16 (-1.26 – 0.94) 0.77 
Total Comorbidities      0.06 (-0.18 – 0.30) 0.63 
Total Medications      -0.05 (-0.25 – 0.15) 0.62 
Table 3. Mean Drop in Orthostatic Blood Pressure at 5 Minutes Blood Pressure and Antidepressant Use. SBP: Systolic Blood Pressure; 
DBP: Diastolic Blood Pressure, BP: Blood Pressure, SSRI: Selective Serotonin Reuptake Inhibitor; SNRI: Serotonin-Noradrenaline Reuptake 
Inhibtor. * = p<0.05 
 
 












Classical OH (cOH): [1 Minute]       
 Model 1  Model 2  Model 3  
 OR (95% CI)  P  OR (95% CI)  P  OR (95% CI) P  
Antidepressant Use 1.32 (0.81 – 2.15) 0.27 1.54 (0.87 – 2.73) 0.13 1.49 (0.82 – 2.69) 0.19 
SSRI 1.68 (1.01 – 2.78) 0.04* 2.03 (1.13 – 3.65) 0.01* 1.98 (1.08 – 3.61) 0.02* 
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Mirtazepine  0.79 (0.23 – 2.74) 0.71 0.93 (0.27 – 3.25) 0.91 0.93 (0.26 – 3.28) 0.90 
SNRI  0.53 (0.12 – 2.32) 0.40 0.70 (0.16 – 3.14) 0.64 0.70 (0.15 – 3.19) 0.65 
Age    1.01 (0.98 – 1.04) 0.62 1.01 (0.97 – 1.04) 0.71 
Gender    0.95 (0.55 – 1.64) 0.86 0.93 (0.54 – 1.61) 0.80 
BMI    0.98 (0.92 – 1.05) 0.56 0.98 (0.92 – 1.05) 0.56 
History of Depression/Anxiety   0.75 (0.36 – 1.57) 0.44 0.74 (0.35 – 1.55) 0.42 
Culprit Medications     0.88 (0.49 – 1.60) 0.68 
Total Comorbidities      1.06 (0.94 – 1.20) 0.32 
Total Medications     0.98 (0.88 – 1.10) 0.75 
       
Delayed OH (dOH) [5 minutes]       
 Model 1  Model 2  Model 3  
 OR (95% CI)  P  OR (95% CI)  P  OR (95% CI) P  
Antidepressant Use 0.91 (0.53 – 1.53) 0.72 1.54 (0.87 – 2.73) 0.93 0.95 (0.51 – 1.79) 0.87 
SSRI 0.81 (0.46 – 1.46) 0.50 0.82 (0.42 – 1.61) 0.57 0.80 (0.40 – 1.58) 0.51 
Mirtazepine  1.06 (0.85 – 1.34) 0.71 1.10 (0.99 – 1.07) 0.49 1.09 (0.98 – 1.06) 0.50 
SNRI  1.84 (0.62 – 5.42) 0.27 1.76 (0.52 – 5.94) 0.36 0.70 (0.15 – 3.19) 0.65 
Age    1.03 (0.90 – 1.07) 0.10 1.02 (0.99 – 1.06) 0.20 
Gender    0.74 (0.42 – 1.31) 0.30 0.72 (0.41 – 1.28) 0.27 
BMI    0.99 (0.92 – 1.06) 0.73 0.98 (0.92 – 1.05) 0.63 
History of Depression/Anxiety   0.99 (0.45 – 2.16) 0.98 0.95 (0.43 – 2.06) 0.89 
Culprit Medications     0.95 (0.51 – 1.76) 0.86 
Total Comorbidities      1.11 (0.97 – 1.26) 0.12 
Total Medications     0.98 (0.87 – 1.10) 0.72 
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Table 4. Logistic Regression Examining the Impact of Antidepressant Use and classical OH/delayed OH. SBP: Systolic Blood Pressure; 
DBP: Diastolic Blood Pressure, BP: Blood Pressure, SSRI: Selective Serotonin Reuptake Inhibitor; SNRI: Serotonin-Noradrenaline Reuptake 
Inhibitor. * = p<0.05 
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